TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company's leadership in adopting responsible practices that drive business resilience and improve our world. The DJSI World Index is a leading benchmark for corporate responsi ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.Regeneron Underperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchEylea Sales Decline Hampers REGN's Ophthalmology UnitEylea is an ...

LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Regeneron investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you ca ...

BENSALEM, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) investors concerning the Company's possible violations of federal securities laws. On April 10, 2024, the US Department of Justice ("DOJ") announced the United States had filed a complaint against Regeneron under the False Claims Act. That announcement stated the complaint "alleges that Regeneron fraudulently in ...

LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 10, 2024, the US Department of Justice (“DOJ”) announced the United States had filed a complaint against Regeneron under the False Claims Act. Th ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Marion McCourt - EVP, Commercial Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone. Thanks so much for joining us. Day one of our healthcare conference. My name is Akash Tewari. I'm a pharma and biotech analyst here at Jefferies. This is the Regeneron management team. We have Ryan, Head ...

Have you looked at biotech stocks lately? Wall Street darlings like Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), Amgen Inc. ( AMGN ), and many other healthcare and biotech stocks have been demolished in recent trading sessions. Even the well-diversified iShares Biotechnology ETF (Are You Getting The Returns You Want? Invest alongside the Financial Prophet's All-Weather Portfolio (2023 47% return) and achieve optimal results in any market.The Daily Prophet Report provides crucial information before the o ...

FDA Review and Dupixent's Potential in CSU - The FDA has accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent to treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older who are inadequately controlled by H1 antihistamines [1] - The target action date for the FDA decision is April 18, 2025, and if approved, Dupixent would be the first targeted therapy for CSU in a decade [1] - The resubmitted sBLA includes new pivotal data from Study C of the LIBERTY-CUPID phase 3 clinical program, which confirmed Dupixent significantly reduced itch and hive activity in patients with uncontrolled CSU [2] Clinical Data and Safety Profile - Study C, part of the LIBERTY-CUPID phase 3 program, met its primary and key secondary endpoints, showing Dupixent's efficacy in reducing itch and urticaria activity [2] - Safety results across all LIBERTY-CUPID phase 3 studies were consistent with Dupixent's known safety profile, with injection site reactions and COVID-19 infection being the most common adverse events (≥5%) compared to placebo [3] Market and Regulatory Landscape - More than 300,000 people in the US suffer from CSU that is inadequately controlled by antihistamines, highlighting a significant unmet medical need [4] - Dupixent has already been approved for CSU in Japan and the United Arab Emirates and is under regulatory review in the EU [6] - Globally, more than 1,000,000 patients are currently being treated with Dupixent across various indications, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [8] Dupixent's Mechanism and Development - Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways, which are key drivers of type-2 inflammation [7] - The Dupilumab development program, a collaboration between Sanofi and Regeneron, has studied over 10,000 patients across more than 60 clinical trials for various chronic diseases driven by type-2 inflammation [9] - Dupilumab is also being investigated in phase 3 studies for other conditions, such as chronic pruritus of unknown origin and bullous pemphigoid [10] Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases, with a strong pipeline in allergic and inflammatory diseases, cancer, and rare diseases [11] - Sanofi is a global healthcare company dedicated to improving lives through innovative treatments and vaccines, with a focus on sustainability and social responsibility [14]

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on Tuesday, November 19, 2024 • Piper Sandler 36th Annual Healthcare Conference at 9:30 a.m. ET on Thursday, December 5, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transc ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one yearDupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial Paris and Tarrytown, NY, ...